Article Details
Retrieved on: 2025-07-02 14:07:19
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The primary end point for the study is radiographic progression-free survival (rPFS) at 12 months. According to RedHill Biopharma, the trial will also ...
Article found on: www.urologytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here